KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Medpace Holdings (MEDP) over the last 11 years, with Q3 2025 value amounting to $239.0 million.

  • Medpace Holdings' Net Cash Flow rose 6495.72% to $239.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$374.7 million, marking a year-over-year decrease of 16668.48%. This contributed to the annual value of $426.5 million for FY2024, which is 9735.87% up from last year.
  • As of Q3 2025, Medpace Holdings' Net Cash Flow stood at $239.0 million, which was up 6495.72% from -$398.1 million recorded in Q2 2025.
  • In the past 5 years, Medpace Holdings' Net Cash Flow registered a high of $239.0 million during Q3 2025, and its lowest value of -$398.1 million during Q2 2025.
  • For the 5-year period, Medpace Holdings' Net Cash Flow averaged around $759526.3, with its median value being $17.9 million (2023).
  • As far as peak fluctuations go, Medpace Holdings' Net Cash Flow plummeted by 76414.48% in 2022, and later soared by 419956.25% in 2023.
  • Quarter analysis of 5 years shows Medpace Holdings' Net Cash Flow stood at $64.2 million in 2021, then crashed by 105.7% to -$3.7 million in 2022, then surged by 4199.56% to $149.9 million in 2023, then tumbled by 90.33% to $14.5 million in 2024, then surged by 1548.58% to $239.0 million in 2025.
  • Its Net Cash Flow stands at $239.0 million for Q3 2025, versus -$398.1 million for Q2 2025 and -$230.1 million for Q1 2025.